FDA Approves Pembrolizumab Plus Axitinib for Advanced RCC

TUESDAY, April 23, 2019 -- The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the U.S. Food and Drug Administration announced Friday. The agency approved the drug...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news